MBT-0312 Uses, Dosage, Side Effects and more
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
| Trade Name | MBT-0312 |
| Generic | MBT-0312 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in solid tumors.
How MBT-0312 works
The already approved and accepted therapy of anti-angiogenesis (suppressing tumor vascularization), is complemented by MBT-0312. An innovative proprietary carrier system of lipid complexes facilitates a novel application method of established cytostatic drugs (e.g. Taxane), intended to cause specific attachment and destruction of tumor blood vessels ("neovascular targeting").
